USPTO serial 79381392
EPROTEIN DISCOVERY
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 1, 2025
- Examiner
- DAVIS, ALEXIS A
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with EPROTEIN DISCOVERY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Rebecca Liebowitz
Rebecca Liebowitz Venable LLPP.O. Box 34385Washington, DC 20043-9998United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical preparations for scientific purposes; chemical preparations, enzymes, gene editing enzymes, oligonucleotides, and proteins for scientific and industrial purposes; genes, DNA and RNA being nucleic acid sequences for scientific and industrial purposes; nucleic acids comprising natural and synthetic nucleotides and oligonucleotides for scientific and industrial purposes; synthetic DNA, synthetic RNA and synthetic genes being nucleic acid sequences for scientific and industrial purposes; synthetic oligonucleotides and synthetic proteins for scientific and industrial use; chemicals, reagents and enzymes for use in the preparation and creation of synthetic DNA, synthetic RNA, synthetic genes being nucleic acid sequences for scientific and industrial purposes; molecular biology research tools in the nature of biological and biochemical reagents; molecular biology research tools in the nature of chemical, biological and biochemical reagents used for the synthesis of DNA, RNA, oligonucleotides, genes and proteins for scientific and industrial purposes | ACTIVE | — |
| 005 | Biological, chemical and biochemical reagents, namely, proteins, and gene editing enzymes, all for medical diagnostic use; synthetic proteins for medical diagnostic use; vaccines | ACTIVE | — |
| 009 | Scientific laboratory apparatus and instruments, namely, scientific desktop instruments for DNA, RNA, gene and protein synthesis for scientific use; scientific desktop instruments for DNA, RNA, gene and protein synthesis, namely, microfluidic devices; medical laboratory research instruments in the nature of desktop instrument cartridges for use in scientific apparatus in connection with DNA, RNA, gene, cell and protein synthesis and characterization instruments, namely microfluidic devices; semiconductors; semiconductor chips; microchips; bio sensors in the nature of sensor chips for scientific, research or industrial purposes in DNA, RNA, gene and protein synthesis; biochips in the nature of microchips; scientific research and laboratory apparatus, namely, apparatus and instruments for amplifying DNA and RNA, namely, reactors, bioreactors, and laboratory apparatus and instruments for amplifying DNA and RNA using thermocyclers, not for medical purposes; apparatus and instruments for synthesising DNA and RNA, namely, microarrays, scientific desktop instruments, desktop instrument cartridges, semiconductors, semiconductor chips, microchips, bio sensors, and bio-chips, not for medical purposes; scientific research and laboratory apparatus, namely, apparatus and instruments for processing DNA and RNA, namely scientific desktop instruments, desktop instrument cartridges, semiconductors, semiconductor chips, microchips, biosensors, and biochips; computer hardware; recorded computer software, downloadable computer software and bioinformatics software for use in DNA, RNA, gene and protein synthesis in the fields of biotechnology, drug discovery and medical science; all of the foregoing for use in DNA, RNA, gene and protein synthesis in the fields of biotechnology and medical science | ACTIVE | — |
| 010 | Medical apparatus and instruments used for DNA and RNA testing and analysis and genetic testing, all for medical purposes; apparatus and instruments for DNA and RNA analysis, DNA and RNA sequencing and protein synthesis in the nature of microfluidic chips, microfluidic cartridges, micro-electromechanical chips, bio sensors, and bio-chips for medical and veterinary purposes; apparatus for DNA, RNA, gene and protein synthesis in the nature of microfluidic chips, microfluidic cartridges, micro-electromechanical chips, bio sensors, and bio-chips for medical and veterinary purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Nuclera Ltd
- Other trademarks owned by Nuclera Ltd
- Other trademarks owned by Nuclera Ltd
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Similar marks named EPROTEIN DISCOVERY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 1, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Apr 1, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 1, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 1, 2025 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Mar 1, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 1, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 11, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 11, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 5, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 22, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 2, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 2, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 2, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 2, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 26, 2024 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Aug 26, 2024 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Aug 26, 2024 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Aug 17, 2024 | RFNP | REFUSAL PROCESSED BY IB | — |
| Aug 5, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 5, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 5, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 16, 2024 | GEAN | NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Jul 16, 2024 | GEAP | EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Jul 16, 2024 | EPEN | COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY | — |
| Jul 16, 2024 | CPEA | EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED | — |
| Jun 25, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 25, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 25, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 2, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 11, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 11, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 10, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 10, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 5, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 24, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 20, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 19, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |